Soligenix, Inc. Files 8-K Report
Ticker: SNGX · Form: 8-K · Filed: Aug 18, 2025 · CIK: 812796
| Field | Detail |
|---|---|
| Company | Soligenix, Inc. (SNGX) |
| Form Type | 8-K |
| Filed Date | Aug 18, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 3 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-k, financial-reporting
TL;DR
SOLIGENIX FILES 8-K: ROUTINE FINANCIAL DISCLOSURE.
AI Summary
On August 18, 2025, Soligenix, Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, indicating a routine update or disclosure related to the company's financial status. No specific new events or material changes were detailed in the provided excerpt.
Why It Matters
This filing serves as a public record of Soligenix, Inc.'s financial disclosures, providing transparency to investors and stakeholders regarding the company's financial health and reporting.
Risk Assessment
Risk Level: low — The filing is a standard 8-K for financial statements and exhibits, with no indication of significant new risks or events.
Key Players & Entities
- SOLIGENIX, INC. (company) — Filer
- August 18, 2025 (date) — Date of Report
- 001-14778 (other) — Commission File Number
- DELAWARE (other) — State of Incorporation
- 41-1505029 (other) — I.R.S. Employer Identification Number
- 29 Emmons Drive, Suite B-10 Princeton, NJ 08540 (address) — Principal Executive Offices
FAQ
What is the primary purpose of this 8-K filing by Soligenix, Inc.?
The primary purpose of this 8-K filing is to report 'Other Events' and 'Financial Statements and Exhibits' as of August 18, 2025.
What is the Commission File Number for Soligenix, Inc.?
The Commission File Number for Soligenix, Inc. is 001-14778.
In which state is Soligenix, Inc. incorporated?
Soligenix, Inc. is incorporated in Delaware.
What is the business address of Soligenix, Inc.?
The business address of Soligenix, Inc. is 29 Emmons Drive, Suite B-10, Princeton, NJ 08540.
What was the former name of Soligenix, Inc. prior to its current name?
The filing indicates former names including DOR BIOPHARMA INC, ENDOREX CORP, and IMMUNOTHERAPEUTICS INC, with dates of name changes in 2002, 1996, and 1992 respectively.
Filing Stats: 737 words · 3 min read · ~2 pages · Grade level 11.3 · Accepted 2025-08-18 09:00:15
Filing Documents
- sngx-20250818x8k.htm (8-K) — 39KB
- sngx-20250818xex99d1.htm (EX-99.1) — 33KB
- sngx-20250818xex99d1001.jpg (GRAPHIC) — 14KB
- 0001558370-25-011625.txt ( ) — 219KB
- sngx-20250818.xsd (EX-101.SCH) — 4KB
- sngx-20250818_def.xml (EX-101.DEF) — 3KB
- sngx-20250818_lab.xml (EX-101.LAB) — 17KB
- sngx-20250818_pre.xml (EX-101.PRE) — 10KB
- sngx-20250818x8k_htm.xml (XML) — 5KB
01
Item 8.01. Other Events. On August 18, 2025, Soligenix, Inc. (the "Company") issued a press release announcing that the Office of Orphan Products Development of the United States Food and Drug Administration has granted orphan drug designation to dusquetide, the active ingredient in SGX945, for "treatment of Behet's Disease" following review of recent Phase 2a clinical results demonstrating biological efficacy and safety in patients with Behet's Disease. A copy of the press release is filed as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference. Safe Harbor for Forward-Looking Statements Certain statements contained in this report may constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including statements containing the words "predicts," "plans," "expects," "anticipates," "believes," "goal," "target," "estimate," "potential," "may," "might," "could," "see," "seek," "forecast," and similar words. Forward-looking statements are based on the Company's current plans and expectations and involve risks and uncertainties which are, in many instances, beyond the Company's control, and which could cause actual results to differ materially from those included in or contemplated or implied by the forward-looking statements. Such risks and uncertainties include, among others, the risks, uncertainties and factors detailed in the Company's filings with the U.S. Securities and Exchange Commission (the "SEC"), including in the Company's Annual Report for the year ended December 31, 2024 on Form 10-K, which was filed with the SEC, and in other periodic reports on Form 10-Q and Form 8-K. As a result of such risks, uncertainties and factors, the Company's actual results may differ materially from
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Press release dated August 18, 2025 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) 2 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Soligenix, Inc. August 18, 2025 By: /s/ Christopher J. Schaber Christopher J. Schaber, Ph.D. President and Chief Executive Officer (Principal Executive Officer) 3